XML 35 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Revenue:    
License and collaboration revenue $ 5,000 $ 50,000
Total revenue 5,000 50,000
Operating expenses:    
Research and development (includes $3,524 and $3,041 from related parties, respectively) 139,139 60,033
General and administrative (includes $0 and $8 from related parties, respectively) 29,749 17,114
Acquired in-process research and development   10,000
Total operating expenses 168,888 87,147
Loss from operations (163,888) (37,147)
Other income, net:    
Fair value adjustments to convertible notes (846) (300)
Other income, net 8,175 624
Total other income (expense), net 7,329 324
Loss before income taxes (156,559) (36,823)
Income tax provision (429) (301)
Net loss to common stockholders $ (156,988) $ (37,124)
Net loss per share attributable to common stockholders - basic (in dollars per share) $ (11.89) $ (24.25)
Net loss per share attributable to common stockholders - diluted (in dollars per share) $ (11.89) $ (24.25)
Weighted-average common stock outstanding - basic (in shares) 13,198,960 1,531,178
Weighted-average common stock outstanding - diluted (in shares) 13,198,960 1,531,178
Comprehensive loss:    
Net loss to common stockholders $ (156,988) $ (37,124)
Other comprehensive income:    
Unrealized gain on marketable securities, net tax 31  
Foreign currency translation adjustment 126 78
Comprehensive loss $ (156,831) $ (37,046)